Strata Critical Medical, Inc. 8K

Strata Critical Medical reported strong Q2 2026 revenue growth, completed multiple clinical acquisitions, signed a major customer-transition agreement, and increased its 2026 revenue and Adjusted EBITDA guidance despite reporting a GAAP net loss.

Strata Critical Medical, Inc. reported its second quarter 2026 results, highlighting a 60.7% year-over-year increase in revenue to $72.5 million driven by growth in its Logistics segment and the expanded Clinical business, while posting a net loss from continuing operations of $10.5 million but improving profitability metrics with Adjusted EBITDA of $7.9 million and positive free cash flow; during the quarter the company completed three bolt-on clinical acquisitions (Louisville Perfusion Services, Heart and Lung Transplant National Recovery Program, and Ohio Valley Perfusion Associates), signed an agreement to assume Statline's Transplant Center Organ Placement customer relationships, and raised its full-year 2026 revenue and Adjusted EBITDA guidance to reflect stronger-than-expected operational performance and M&A contributions.

Filing Facts

CIK

1779128

Ticker

-

Form

8K

Source Type

sec

Accession

0001628280-26-052152

Alert Tier

7